Nektar Therapeutics (NKTR)
USD 0.49
(0.39%)
USD 0.49
(0.39%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -137.42 Million USD | 42.8% |
| 2022 | -240.23 Million USD | 46.15% |
| 2021 | -446.1 Million USD | -17.42% |
| 2020 | -379.92 Million USD | 13.66% |
| 2019 | -440.03 Million USD | -163.96% |
| 2018 | 687.93 Million USD | 1253.44% |
| 2017 | -59.64 Million USD | 47.15% |
| 2016 | -112.85 Million USD | -284.24% |
| 2015 | -29.37 Million USD | -78.17% |
| 2014 | -16.48 Million USD | 86.28% |
| 2013 | -120.13 Million USD | 14.92% |
| 2012 | -141.2 Million USD | -13.93% |
| 2011 | -123.93 Million USD | -338.64% |
| 2010 | -28.25 Million USD | 70.3% |
| 2009 | -95.13 Million USD | -15.1% |
| 2008 | -82.65 Million USD | -128.65% |
| 2007 | -36.14 Million USD | 77.3% |
| 2006 | -159.23 Million USD | 12.81% |
| 2005 | -182.63 Million USD | -146.99% |
| 2004 | -73.94 Million USD | -11.72% |
| 2003 | -66.18 Million USD | 33.87% |
| 2002 | -100.08 Million USD | 61.05% |
| 2001 | -256.96 Million USD | -288.52% |
| 2000 | -66.13 Million USD | -63.37% |
| 1999 | -40.48 Million USD | -84.1% |
| 1998 | -21.99 Million USD | -60.23% |
| 1997 | -13.72 Million USD | -19.34% |
| 1996 | -11.5 Million USD | -30.68% |
| 1995 | -8.8 Million USD | -54.39% |
| 1994 | -5.7 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -36.48 Million USD | -5.9% |
| 2024 Q1 | -34.45 Million USD | -12.37% |
| 2023 Q4 | -30.66 Million USD | 31.66% |
| 2023 Q3 | -44.86 Million USD | 11.33% |
| 2023 Q2 | -50.59 Million USD | -36.69% |
| 2023 FY | -137.42 Million USD | 42.8% |
| 2023 Q1 | -37.01 Million USD | 9.47% |
| 2022 FY | -240.23 Million USD | 46.15% |
| 2022 Q4 | -40.88 Million USD | -9.12% |
| 2022 Q3 | -37.47 Million USD | 19.92% |
| 2022 Q2 | -46.79 Million USD | 59.34% |
| 2022 Q1 | -115.08 Million USD | -1.93% |
| 2021 FY | -446.1 Million USD | -17.42% |
| 2021 Q2 | -110.2 Million USD | -0.74% |
| 2021 Q3 | -113.59 Million USD | -3.08% |
| 2021 Q4 | -112.91 Million USD | 0.6% |
| 2021 Q1 | -109.39 Million USD | 1.2% |
| 2020 Q1 | -133.63 Million USD | -21.88% |
| 2020 Q3 | -103.05 Million USD | -32.61% |
| 2020 Q2 | -77.7 Million USD | 41.85% |
| 2020 Q4 | -110.72 Million USD | -7.44% |
| 2020 FY | -379.92 Million USD | 13.66% |
| 2019 Q1 | -120.68 Million USD | -20.33% |
| 2019 Q2 | -110.97 Million USD | 8.05% |
| 2019 Q3 | -98.74 Million USD | 11.02% |
| 2019 Q4 | -109.63 Million USD | -11.04% |
| 2019 FY | -440.03 Million USD | -163.96% |
| 2018 Q1 | -86.73 Million USD | -260.9% |
| 2018 Q3 | -98.63 Million USD | -110.13% |
| 2018 Q2 | 973.6 Million USD | 1222.45% |
| 2018 Q4 | -100.29 Million USD | -1.68% |
| 2018 FY | 687.93 Million USD | 1253.44% |
| 2017 Q1 | -54.43 Million USD | -69.35% |
| 2017 Q3 | 69.48 Million USD | 237.17% |
| 2017 Q4 | -24.03 Million USD | -134.59% |
| 2017 FY | -59.64 Million USD | 47.15% |
| 2017 Q2 | -50.65 Million USD | 6.95% |
| 2016 Q1 | -9.48 Million USD | 67.7% |
| 2016 Q3 | -32.9 Million USD | 14.15% |
| 2016 Q4 | -32.14 Million USD | 2.3% |
| 2016 FY | -112.85 Million USD | -284.24% |
| 2016 Q2 | -38.32 Million USD | -304.1% |
| 2015 Q4 | -29.36 Million USD | -7108.11% |
| 2015 Q2 | -43.46 Million USD | -200.99% |
| 2015 FY | -29.37 Million USD | -78.17% |
| 2015 Q3 | 419 Thousand USD | 100.96% |
| 2015 Q1 | 43.04 Million USD | 214.82% |
| 2014 Q1 | -36.4 Million USD | -1.42% |
| 2014 FY | -16.48 Million USD | 86.28% |
| 2014 Q2 | -22.91 Million USD | 37.05% |
| 2014 Q3 | 80.32 Million USD | 450.5% |
| 2014 Q4 | -37.48 Million USD | -146.67% |
| 2013 Q4 | -35.89 Million USD | -450.1% |
| 2013 Q2 | -32.6 Million USD | 28.19% |
| 2013 FY | -120.13 Million USD | 14.92% |
| 2013 Q1 | -45.4 Million USD | -4.66% |
| 2013 Q3 | -6.52 Million USD | 79.99% |
| 2012 Q1 | -37.93 Million USD | -10.05% |
| 2012 FY | -141.2 Million USD | -13.93% |
| 2012 Q4 | -43.38 Million USD | -31.86% |
| 2012 Q3 | -32.9 Million USD | -21.91% |
| 2012 Q2 | -26.98 Million USD | 28.85% |
| 2011 Q3 | -21.33 Million USD | 37.72% |
| 2011 Q2 | -34.26 Million USD | -1.17% |
| 2011 Q4 | -34.46 Million USD | -61.53% |
| 2011 FY | -123.93 Million USD | -338.64% |
| 2011 Q1 | -33.86 Million USD | -64.89% |
| 2010 Q2 | 1.86 Million USD | 155.6% |
| 2010 FY | -28.25 Million USD | 70.3% |
| 2010 Q4 | -20.53 Million USD | -229.94% |
| 2010 Q3 | -6.22 Million USD | -433.42% |
| 2010 Q1 | -3.35 Million USD | 38.89% |
| 2009 Q3 | -28.85 Million USD | 5.32% |
| 2009 Q1 | -30.29 Million USD | -211.57% |
| 2009 FY | -95.13 Million USD | -15.1% |
| 2009 Q4 | -5.49 Million USD | 80.96% |
| 2009 Q2 | -30.48 Million USD | -0.6% |
| 2008 Q1 | -41.88 Million USD | -212.06% |
| 2008 Q3 | -34.56 Million USD | -3.61% |
| 2008 Q4 | 27.15 Million USD | 178.57% |
| 2008 FY | -82.65 Million USD | -128.65% |
| 2008 Q2 | -33.35 Million USD | 20.37% |
| 2007 Q1 | -25.96 Million USD | 35.34% |
| 2007 Q3 | -19.57 Million USD | 30.07% |
| 2007 FY | -36.14 Million USD | 77.3% |
| 2007 Q2 | -27.98 Million USD | -7.77% |
| 2007 Q4 | 37.38 Million USD | 290.99% |
| 2006 FY | -159.23 Million USD | 12.81% |
| 2006 Q4 | -40.16 Million USD | -77.07% |
| 2006 Q3 | -22.68 Million USD | 64.12% |
| 2006 Q2 | -63.21 Million USD | -90.55% |
| 2006 Q1 | -33.17 Million USD | 69.49% |
| 2005 Q1 | -24.09 Million USD | -36.42% |
| 2005 Q2 | -26.45 Million USD | -9.79% |
| 2005 Q3 | -23.36 Million USD | 11.66% |
| 2005 Q4 | -108.72 Million USD | -365.29% |
| 2005 FY | -182.63 Million USD | -146.99% |
| 2004 Q2 | -21.11 Million USD | -30.93% |
| 2004 Q3 | -19.03 Million USD | 9.85% |
| 2004 Q4 | -17.66 Million USD | 7.23% |
| 2004 FY | -73.94 Million USD | -11.72% |
| 2004 Q1 | -16.12 Million USD | 18.99% |
| 2003 Q3 | -14.13 Million USD | 3.22% |
| 2003 FY | -66.18 Million USD | 33.87% |
| 2003 Q4 | -19.9 Million USD | -40.87% |
| 2003 Q2 | -14.6 Million USD | 16.74% |
| 2003 Q1 | -17.54 Million USD | 40.02% |
| 2002 Q3 | -24.58 Million USD | -8.41% |
| 2002 Q2 | -22.67 Million USD | 3.83% |
| 2002 FY | -100.08 Million USD | 61.05% |
| 2002 Q1 | -23.57 Million USD | 28.12% |
| 2002 Q4 | -29.24 Million USD | -18.96% |
| 2001 Q4 | -32.8 Million USD | -15.14% |
| 2001 Q3 | -28.49 Million USD | 74.04% |
| 2001 FY | -256.96 Million USD | -288.52% |
| 2001 Q2 | -109.73 Million USD | -27.7% |
| 2001 Q1 | -85.93 Million USD | -381.76% |
| 2000 Q4 | -17.83 Million USD | -11.91% |
| 2000 Q2 | -17.59 Million USD | -19.11% |
| 2000 Q1 | -14.77 Million USD | 26.08% |
| 2000 FY | -66.13 Million USD | -63.37% |
| 2000 Q3 | -15.93 Million USD | 9.41% |
| 1999 FY | -40.48 Million USD | -84.1% |
| 1999 Q2 | -6.66 Million USD | -7.56% |
| 1999 Q1 | -6.2 Million USD | 9.42% |
| 1999 Q4 | -19.98 Million USD | -161.78% |
| 1999 Q3 | -7.63 Million USD | -14.45% |
| 1998 FY | -21.99 Million USD | -60.23% |
| 1998 Q4 | -6.84 Million USD | -16.47% |
| 1998 Q3 | -5.87 Million USD | -47.26% |
| 1998 Q2 | -3.99 Million USD | 24.37% |
| 1998 Q1 | -5.27 Million USD | -22.75% |
| 1997 Q1 | -2.74 Million USD | 27.79% |
| 1997 Q4 | -4.29 Million USD | -24.14% |
| 1997 Q3 | -3.46 Million USD | -8.63% |
| 1997 Q2 | -3.18 Million USD | -16.18% |
| 1997 FY | -13.72 Million USD | -19.34% |
| 1996 Q2 | -3 Million USD | -42.86% |
| 1996 Q3 | -2.7 Million USD | 10.0% |
| 1996 Q4 | -3.8 Million USD | -40.74% |
| 1996 FY | -11.5 Million USD | -30.68% |
| 1996 Q1 | -2.1 Million USD | 16.0% |
| 1995 Q1 | -2.3 Million USD | 4.17% |
| 1995 Q3 | -2 Million USD | 0.0% |
| 1995 Q4 | -2.5 Million USD | -25.0% |
| 1995 FY | -8.8 Million USD | -54.39% |
| 1995 Q2 | -2 Million USD | 13.04% |
| 1994 Q4 | -2.4 Million USD | -118.18% |
| 1994 FY | -5.7 Million USD | 0.0% |
| 1994 Q2 | -1.1 Million USD | -10.0% |
| 1994 Q1 | -1 Million USD | 0.0% |
| 1994 Q3 | -1.1 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Akebia Therapeutics, Inc. | -46.25 Million USD | -197.097% |
| Jaguar Health, Inc. | -34.29 Million USD | -300.761% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 19.134% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | -142.12% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 51.298% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | 1250.77% |
| ContextLogic Inc. | -328 Million USD | 58.102% |
| MiMedx Group, Inc. | 37.11 Million USD | 470.258% |
| MEI Pharma, Inc. | 14.54 Million USD | 1045.021% |
| AlloVir, Inc. | -181.33 Million USD | 24.213% |
| Novavax, Inc. | -566.51 Million USD | 75.742% |
| Aptorum Group Limited | -10.52 Million USD | -1205.908% |
| Ardelyx, Inc. | -63.27 Million USD | -117.183% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 32.964% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -4893.959% |
| Vaxcyte, Inc. | -468.04 Million USD | 70.638% |
| Precigen, Inc. | -88.92 Million USD | -54.544% |
| Pharming Group N.V. | -4.87 Million USD | -2716.349% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 17.863% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | -361.84% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | -570.66% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 41.67% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | -607.701% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | -465.381% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | -465.381% |
| Bicycle Therapeutics plc | -189.94 Million USD | 27.65% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 49.846% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | -368.947% |
| Acelyrin, Inc. | -422.06 Million USD | 67.44% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | -262.896% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | -270.778% |
| Senti Biosciences, Inc. | -92.72 Million USD | -48.204% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | -19.736% |
| AbCellera Biologics Inc. | -237.2 Million USD | 42.065% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | -301.042% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 20.0% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | -4246.142% |
| Chimerix, Inc. | -93.06 Million USD | -47.666% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | -316.175% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -683.54% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -204.865% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | -171.093% |
| Elevation Oncology, Inc. | -45.44 Million USD | -202.399% |
| Alkermes plc | 414.12 Million USD | 133.185% |
| Fortress Biotech, Inc. | -142.34 Million USD | 3.454% |
| Fortress Biotech, Inc. | -142.34 Million USD | 3.454% |
| Agenus Inc. | -159.54 Million USD | 13.867% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | -40.669% |
| Dyadic International, Inc. | -8.22 Million USD | -1569.859% |
| ImmuCell Corporation | -5.74 Million USD | -2290.799% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | -11428.943% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | -2.229% |
| Lantern Pharma Inc. | -17.87 Million USD | -668.701% |
| Immix Biopharma, Inc. | -16.14 Million USD | -751.397% |
| Incyte Corporation | 620.52 Million USD | 122.147% |
| IO Biotech, Inc. | -91.44 Million USD | -50.285% |
| Janux Therapeutics, Inc. | -72.97 Million USD | -88.308% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | -584.054% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | -158.676% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | -6.541% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | -1516.575% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | -63.769% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 63.883% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 72.75% |
| NextCure, Inc. | -67.63 Million USD | -103.18% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | -1201.004% |
| Onconetix, Inc. | -36.03 Million USD | -281.37% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | -229.446% |
| Opthea Limited | -191.84 Million USD | 28.366% |
| PDS Biotechnology Corporation | -43.04 Million USD | -219.257% |
| PureTech Health plc | -146.19 Million USD | 6.001% |
| Pyxis Oncology, Inc. | -82.19 Million USD | -67.192% |
| Seer, Inc. | -103.46 Million USD | -32.825% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | -1065628.107% |
| Clearside Biomedical, Inc. | -24.84 Million USD | -453.152% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | -3386.132% |
| VYNE Therapeutics Inc. | -29.25 Million USD | -369.701% |
| Wave Life Sciences Ltd. | -67.99 Million USD | -102.107% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | -212.259% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 1.155% |
| ChromaDex Corporation | -5.59 Million USD | -2354.456% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -1892.244% |
| Caribou Biosciences, Inc. | -116.05 Million USD | -18.41% |
| CRISPR Therapeutics AG | -222.53 Million USD | 38.247% |
| Precision BioSciences, Inc. | -43.73 Million USD | -214.215% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 27.865% |
| Innoviva, Inc. | 176.7 Million USD | 177.769% |
| Summit Therapeutics Inc. | -89.73 Million USD | -53.144% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | -108.983% |
| Aadi Bioscience, Inc. | -71.93 Million USD | -91.046% |
| ESSA Pharma Inc. | -32.13 Million USD | -327.661% |
| GlycoMimetics, Inc. | -39.27 Million USD | -249.902% |
| GT Biopharma, Inc. | -13.57 Million USD | -912.264% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 37.312% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 258.302% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | -166.814% |
| Alzamend Neuro, Inc. | -9.93 Million USD | -1282.873% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 47.075% |
| Aptose Biosciences Inc. | -52.35 Million USD | -162.482% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | -852.965% |
| Soligenix, Inc. | -7.69 Million USD | -1685.218% |
| Century Therapeutics, Inc. | -146.54 Million USD | 6.224% |
| Kura Oncology, Inc. | -165.8 Million USD | 17.116% |
| TScan Therapeutics, Inc. | -93.45 Million USD | -47.045% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | -1551.941% |
| Ocean Biomedical, Inc. | -2.48 Million USD | -5437.671% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | -2019.448% |
| Autolus Therapeutics plc | -195.02 Million USD | 29.536% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | -62.332% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | -86.562% |
| Eterna Therapeutics Inc. | -21.13 Million USD | -550.225% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 39.47% |
| GRI Bio, Inc. | -11.38 Million USD | -1106.859% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -2943.261% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | -4.75% |
| IGM Biosciences, Inc. | -263.46 Million USD | 47.839% |
| INmune Bio, Inc. | -29.74 Million USD | -362.073% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -24.237% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | -260.929% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | -760.016% |
| Entero Therapeutics, Inc. | -15.77 Million USD | -771.387% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | -124.926% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | -27.811% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 50.209% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 32.369% |
| Verastem, Inc. | -92.08 Million USD | -49.239% |
| Abeona Therapeutics Inc. | -47.13 Million USD | -191.556% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 25.371% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | -16.088% |
| Histogen Inc. | -10.64 Million USD | -1191.224% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | -788.22% |
| Surrozen, Inc. | -45.78 Million USD | -200.186% |
| Organovo Holdings, Inc. | -15.08 Million USD | -810.944% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -2599.777% |
| Ovid Therapeutics Inc. | -59.28 Million USD | -131.818% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -167.916% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | -443.612% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | -1700.443% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 19.767% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | -183.655% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | -75.724% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | -802.878% |
| Apollomics, Inc. | -54.83 Million USD | -150.62% |
| Amarin Corporation plc | -67.58 Million USD | -103.328% |
| Mesoblast Limited | -58.79 Million USD | -133.74% |
| Turnstone Biologics Corp. | -59.03 Million USD | -132.797% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 16.979% |
| Synaptogenix, Inc. | -8.31 Million USD | -1552.964% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | -842.171% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | -49.878% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -2768.12% |
| Monopar Therapeutics Inc. | -8.83 Million USD | -1456.124% |
| Exelixis, Inc. | 170.88 Million USD | 180.42% |
| Better Therapeutics, Inc. | -38.26 Million USD | -259.168% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 11.375% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 73.425% |
| NLS Pharmaceutics AG | -11.8 Million USD | -1063.922% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | -1608.861% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | -358.19% |
| Gritstone bio, Inc. | -154.63 Million USD | 11.129% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | -99.569% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | -702.573% |
| Avid Bioservices, Inc. | -18.67 Million USD | -635.759% |
| Insmed Incorporated | -709.62 Million USD | 80.634% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | -775.888% |
| MediWound Ltd. | -15.29 Million USD | -798.79% |
| OmniAb, Inc. | -69.41 Million USD | -97.965% |
| Alector, Inc. | -151.74 Million USD | 9.434% |
| Seres Therapeutics, Inc. | -107.98 Million USD | -27.265% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | -163.529% |
| Zai Lab Limited | -366.57 Million USD | 62.511% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 56.618% |
| Aura Biosciences, Inc. | -84.99 Million USD | -61.694% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 44.022% |
| Immunic, Inc. | -99.22 Million USD | -38.501% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 4.005% |
| Veracyte, Inc. | -85.79 Million USD | -60.178% |
| InMed Pharmaceuticals Inc. | - USD | Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 51.236% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | -867.101% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | -1895.152% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | -631.271% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 123.752% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | -439.917% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | 454.17% |
| TG Therapeutics, Inc. | 20.63 Million USD | 766.045% |
| Galecto, Inc. | -39.9 Million USD | -244.38% |
| Calithera Biosciences, Inc. | -42.07 Million USD | -226.627% |
| Fortrea Holdings Inc. | 63.1 Million USD | 317.789% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 2.15% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | -375.881% |
| XBiotech Inc. | -37.51 Million USD | -266.369% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | -99.569% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | -104.745% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | -27.356% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | -435.311% |
| Theravance Biopharma, Inc. | -53.29 Million USD | -157.872% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 75.857% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | -75.082% |
| Vaxxinity, Inc. | -58.28 Million USD | -135.781% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | -32.51% |
| Gain Therapeutics, Inc. | -22.25 Million USD | -517.553% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | -59.027% |
| NexImmune, Inc. | -29.19 Million USD | -370.755% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | -2345.227% |
| Marker Therapeutics, Inc. | -14.58 Million USD | -842.469% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 103.396% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | -439.789% |
| Scopus BioPharma Inc. | -11.71 Million USD | -1073.081% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | -8.156% |
| Ainos, Inc. | -13.2 Million USD | -940.594% |
| Pluri Inc. | -22.15 Million USD | -520.205% |
| Prothena Corporation plc | -191.03 Million USD | 28.063% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 0.444% |
| Celularity Inc. | -192.28 Million USD | 28.531% |
| Rallybio Corporation | -78.93 Million USD | -74.106% |
| Cue Biopharma, Inc. | -52.14 Million USD | -163.524% |
| MeiraGTx Holdings plc | -137.06 Million USD | -0.266% |
| Omeros Corporation | -164.53 Million USD | 16.474% |
| Humacyte, Inc. | -100.04 Million USD | -37.36% |
| Immunocore Holdings plc | -59.64 Million USD | -130.389% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | -640.476% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | -461.308% |
| Blueprint Medicines Corporation | -486.27 Million USD | 71.739% |
| CalciMedica, Inc. | -21.87 Million USD | -528.229% |
| Cabaletta Bio, Inc. | -74.66 Million USD | -84.068% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | -4.518% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 19.773% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 57.961% |
| Pulmatrix, Inc. | -14.74 Million USD | -832.327% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | -284.459% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | -54.643% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 73.331% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | -103.439% |
| Cytokinetics, Incorporated | -496.2 Million USD | 72.305% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | -299.271% |
| Nutriband Inc. | -4.87 Million USD | -2720.753% |
| Protara Therapeutics, Inc. | -43.61 Million USD | -215.101% |
| Vor Biopharma Inc. | -126.03 Million USD | -9.036% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 103.24% |
| Evogene Ltd. | -26.39 Million USD | -420.727% |
| ProKidney Corp. | -151.52 Million USD | 9.304% |
| Applied Therapeutics, Inc. | -64.53 Million USD | -112.946% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | -1686.54% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 77.374% |
| CorMedix Inc. | -48.95 Million USD | -180.701% |
| BioLineRx Ltd. | -49.69 Million USD | -176.542% |
| Tango Therapeutics, Inc. | -114.17 Million USD | -20.366% |
| Galectin Therapeutics Inc. | -38.07 Million USD | -260.961% |
| Atai Life Sciences N.V. | -125.47 Million USD | -9.527% |
| Renovaro Biosciences Inc. | -81.63 Million USD | -68.332% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | -68.808% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 44.807% |
| Sagimet Biosciences Inc. | -30.74 Million USD | -347.056% |
| MediciNova, Inc. | -9.9 Million USD | -1288.094% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | -8.746% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -1797.491% |
| GeoVax Labs, Inc. | -26.74 Million USD | -413.874% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 40.72% |
| Biomea Fusion, Inc. | -126.13 Million USD | -8.951% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 60.669% |
| Mereo BioPharma Group plc | -28.41 Million USD | -383.618% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 28.083% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 40.238% |
| Absci Corporation | -115.51 Million USD | -18.967% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | -398.151% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | -21.758% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 43.251% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | -445.424% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 33.928% |
| Allakos Inc. | -196.05 Million USD | 29.905% |
| Imunon, Inc. | -21.03 Million USD | -553.458% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | -24.182% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 228.097% |
| BioAtla, Inc. | -129.68 Million USD | -5.967% |
| NLS Pharmaceutics AG | -11.8 Million USD | -1063.922% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -767.418% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 58.069% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | -229.099% |
| XOMA Corporation | -41.84 Million USD | -228.391% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | -30.586% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -13.112% |
| aTyr Pharma, Inc. | -54.91 Million USD | -150.232% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | -57.188% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 20.504% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 45.991% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | -540.198% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | -1573.312% |
| Akari Therapeutics, Plc | -16.8 Million USD | -717.714% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -1553948.782% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 140.71% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -2003.222% |
| UroGen Pharma Ltd. | -65.53 Million USD | -109.694% |
| Sutro Biopharma, Inc. | -89.27 Million USD | -53.929% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -1792.121% |
| Orgenesis Inc. | -53.63 Million USD | -156.218% |
| Entera Bio Ltd. | -8.89 Million USD | -1445.664% |
| GH Research PLC | -41.22 Million USD | -233.378% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | -434.561% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | -65.467% |
| Xencor, Inc. | -138.63 Million USD | 0.876% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | -2566.074% |
| Replimune Group, Inc. | -234.77 Million USD | 41.465% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | -539.45% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | -884.984% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -2003.222% |
| Portage Biotech Inc. | -18.25 Million USD | -652.89% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -1797.491% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | -30.93% |
| OncoCyte Corporation | -25.13 Million USD | -446.726% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -1115.628% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -1099.479% |
| Purple Biotech Ltd. | 22.27 Million USD | 717.058% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | -1729.406% |
| scPharmaceuticals Inc. | -55.39 Million USD | -148.077% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | -627.205% |
| HilleVax, Inc. | -133.34 Million USD | -3.06% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | -1040.551% |
| Tharimmune, Inc. | -9.45 Million USD | -1353.43% |
| Genprex, Inc. | -31.07 Million USD | -342.228% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 26.977% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | -337.98% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | -17864.052% |
| Virios Therapeutics, Inc. | -5.44 Million USD | -2422.986% |
| OKYO Pharma Limited | -15.74 Thousand USD | -872454.641% |
| Savara Inc. | -60 Million USD | -129.015% |
| Curis, Inc. | -48.33 Million USD | -184.335% |
| Daré Bioscience, Inc. | -30.83 Million USD | -345.608% |
| Carmell Therapeutics Corporation | -5.21 Million USD | -2534.035% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | -1788.484% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | -404.312% |
| BeiGene, Ltd. | -1.2 Billion USD | 88.621% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -589.217% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 71.792% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | -46.74% |
| Erasca, Inc. | -141.52 Million USD | 2.897% |
| bluebird bio, Inc. | -244.26 Million USD | 43.739% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -2935.692% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 170.677% |
| DBV Technologies S.A. | -76.43 Million USD | -79.8% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -2935.692% |
| Moderna, Inc. | -4.23 Billion USD | 96.758% |
| Vincerx Pharma, Inc. | -42.6 Million USD | -222.526% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | -2060.77% |
| Molecular Templates, Inc. | -10.46 Million USD | -1213.061% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | -104.389% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 63.523% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 4.107% |
| Spruce Biosciences, Inc. | -51.99 Million USD | -164.314% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 11.076% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 33.972% |
| MacroGenics, Inc. | -168.24 Million USD | 18.318% |
| RenovoRx, Inc. | -11.39 Million USD | -1105.906% |
| Adicet Bio, Inc. | -152.03 Million USD | 9.611% |
| Prime Medicine, Inc. | -191.29 Million USD | 28.16% |
| Aditxt, Inc. | -26.06 Million USD | -427.292% |
| Adagene Inc. | -23.71 Million USD | -479.367% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -1779.934% |
| Quantum-Si incorporated | -111.17 Million USD | -23.616% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | -334.23% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | -842.703% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | 212.631% |
| SciSparc Ltd. | -5.77 Million USD | -2280.478% |
| Vericel Corporation | -6.46 Million USD | -2026.006% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -1487.505% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | -494.41% |
| Generation Bio Co. | -138.56 Million USD | 0.821% |
| Astria Therapeutics, Inc. | -83.03 Million USD | -65.512% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | -58.946% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 43.001% |
| Invivyd, Inc. | -207.78 Million USD | 33.861% |
| Relay Therapeutics, Inc. | -373 Million USD | 63.157% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | -1365.319% |
| Spero Therapeutics, Inc. | 21.48 Million USD | 739.751% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -1235.909% |
| 2seventy bio, Inc. | -216.7 Million USD | 36.584% |
| ADMA Biologics, Inc. | 21.63 Million USD | 735.286% |
| Clene Inc. | -40.54 Million USD | -238.986% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | -470.753% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | -150.794% |
| GeoVax Labs, Inc. | -26.74 Million USD | -413.874% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 60.742% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | -274.129% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | 954.793% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | -32.519% |
| Finch Therapeutics Group, Inc. | -34 Million USD | -304.167% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 19.294% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 79.918% |
| Evaxion Biotech A/S | -22.19 Million USD | -519.115% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | -66.814% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 38.409% |
| Trevena, Inc. | -35.28 Million USD | -289.438% |
| Surrozen, Inc. | -45.78 Million USD | -200.186% |
| Tyra Biosciences, Inc. | -79.94 Million USD | -71.899% |
| Cingulate Inc. | -22.75 Million USD | -503.822% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | 1934.29% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -207.666% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | -1569.006% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | -33.997% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | -87.281% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | -121.389% |
| Clearmind Medicine Inc. | -8.74 Million USD | -1472.126% |
| Kronos Bio, Inc. | -121.83 Million USD | -12.801% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | -80.357% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -4585.5% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -36.298% |
| Statera Biopharma, Inc. | -98.34 Million USD | -39.739% |
| ImmunityBio, Inc. | -362.25 Million USD | 62.063% |
| Korro Bio, Inc. | -84.53 Million USD | -62.568% |
| Kineta, Inc. | -15.72 Million USD | -774.038% |
| BioVie Inc. | -32.17 Million USD | -327.056% |
| Codexis, Inc. | -68.06 Million USD | -101.891% |
| Celularity Inc. | -192.28 Million USD | 28.531% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 38.266% |
| Celcuity Inc. | -66.23 Million USD | -107.496% |
| Virax Biolabs Group Limited | -6.49 Million USD | -2015.379% |
| Cibus, Inc. | -318.88 Million USD | 56.904% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | -219.593% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | -306.054% |
| IN8bio, Inc. | -30.33 Million USD | -352.995% |
| Kodiak Sciences Inc. | -277.32 Million USD | 50.446% |
| Annexon, Inc. | -143.72 Million USD | 4.382% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | -11.014% |
| Assembly Biosciences, Inc. | -64.64 Million USD | -112.581% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | -486.184% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 61.15% |
| Eyenovia, Inc. | -25.4 Million USD | -440.906% |
| Puma Biotechnology, Inc. | 32.64 Million USD | 521.032% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -2370.784% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | -73.663% |
| Arcellx, Inc. | -89.88 Million USD | -52.898% |
| Cardiff Oncology, Inc. | -45.41 Million USD | -202.618% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | -0.159% |
| Regulus Therapeutics Inc. | -31.1 Million USD | -341.753% |
| Moolec Science SA | -6.65 Million USD | -1965.36% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | -124.778% |
| Geron Corporation | -193.94 Million USD | 29.142% |
| LAVA Therapeutics N.V. | -43.25 Million USD | -217.724% |
| Royalty Pharma plc | 1.49 Billion USD | 109.21% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 16.287% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -1373.274% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | -527.664% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 19.614% |
| Humacyte, Inc. | -100.04 Million USD | -37.36% |
| Structure Therapeutics Inc. | -102.77 Million USD | -33.714% |
| 89bio, Inc. | -151.2 Million USD | 9.113% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | -71.498% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | -845.151% |
| Genelux Corporation | -24.16 Million USD | -468.694% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | -305.109% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 19.985% |
| Notable Labs, Ltd. | -14.65 Million USD | -837.607% |
| Liquidia Corporation | -73.38 Million USD | -87.268% |
| Mustang Bio, Inc. | -50.72 Million USD | -170.916% |
| Immunovant, Inc. | -282.7 Million USD | 51.39% |
| Quantum-Si incorporated | -111.17 Million USD | -23.616% |
| Arbutus Biopharma Corporation | -78.1 Million USD | -75.954% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | -546.189% |
| Vera Therapeutics, Inc. | -102.01 Million USD | -34.715% |
| Acasti Pharma Inc. | -11.31 Million USD | -1114.86% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | -499.557% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | -760.016% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 35.799% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | -3645.497% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -765.07% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | -371.328% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | -232.073% |
| PepGen Inc. | -84.76 Million USD | -62.123% |
| Moleculin Biotech, Inc. | -29.63 Million USD | -363.788% |
| United Therapeutics Corporation | 1.18 Billion USD | 111.598% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | -500.188% |
| Solid Biosciences Inc. | -104.31 Million USD | -31.74% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | -318.875% |
| Immuneering Corporation | -58.41 Million USD | -135.265% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -2599.777% |
| Silo Pharma, Inc. | -3.85 Million USD | -3464.303% |
| Belite Bio, Inc | -31.66 Million USD | -333.955% |
| XOMA Corporation | -41.84 Million USD | -228.391% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | -103.532% |
| Bionomics Limited | -17.89 Billion USD | 99.232% |
| Apogee Therapeutics, Inc. | -93 Million USD | -47.764% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 485.16% |
| uniQure N.V. | -282.87 Million USD | 51.418% |
| Cassava Sciences, Inc. | -105.95 Million USD | -29.699% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -1779.934% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | -6.116% |
| Forte Biosciences, Inc. | -32.48 Million USD | -323.028% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | -1553.978% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | -367.511% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -2370.784% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | -867.101% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | -1446.012% |
| Altimmune, Inc. | -95.92 Million USD | -43.257% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -86.988% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 485.16% |
| Compugen Ltd. | -12.99 Million USD | -957.766% |
| Peak Bio, Inc. | -1356.23 USD | -10132768.319% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | -177.044% |
| Benitec Biopharma Inc. | -22.49 Million USD | -511.049% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 43.284% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | -361.995% |
| Zura Bio Limited | -62.63 Million USD | -119.396% |
| PolyPid Ltd. | -22.86 Million USD | -500.975% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | -744.341% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | -361.995% |
| Instil Bio, Inc. | -159.16 Million USD | 13.661% |
| argenx SE | -425.04 Million USD | 67.668% |
| Immunome, Inc. | -109.53 Million USD | -25.468% |
| Compass Therapeutics, Inc. | -50.36 Million USD | -172.869% |
| Verona Pharma plc | -67.83 Million USD | -102.599% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | -427.341% |
| Shattuck Labs, Inc. | -91.95 Million USD | -49.445% |
| CervoMed Inc. | -7.81 Million USD | -1658.951% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | -87.97% |
| Plus Therapeutics, Inc. | -13.32 Million USD | -931.642% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | -185.268% |
| Moolec Science SA | -6.65 Million USD | -1965.36% |
| Enveric Biosciences, Inc. | -16.44 Million USD | -735.49% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | -1.626% |
| AnaptysBio, Inc. | -164.41 Million USD | 16.414% |
| Design Therapeutics, Inc. | -78.19 Million USD | -75.758% |
| Leap Therapeutics, Inc. | -87.04 Million USD | -57.885% |
| NeurAxis, Inc. | -6.66 Million USD | -1962.047% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | -239.329% |
| Lumos Pharma, Inc. | -36.61 Million USD | -275.335% |
| Achilles Therapeutics plc | -75.25 Million USD | -82.612% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | -427.341% |
| 180 Life Sciences Corp. | -13.47 Million USD | -919.662% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | 2765.181% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -4585.5% |
| Nutriband Inc. | -4.87 Million USD | -2720.753% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | -24.052% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | -147.84% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | -170.33% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | -107.908% |
| MoonLake Immunotherapeutics | -54.12 Million USD | -153.912% |
| Palisade Bio, Inc. | -13.07 Million USD | -951.454% |
| Tourmaline Bio, Inc. | -45.4 Million USD | -202.638% |
| Beam Therapeutics Inc. | -176.48 Million USD | 22.132% |
| Neurogene Inc. | -55.58 Million USD | -147.243% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | -25.9% |
| AEON Biopharma, Inc. | -48.42 Million USD | -183.766% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | -42.1% |
| Sesen Bio, Inc. | -25.9 Million USD | -430.414% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | -64.524% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | -991.81% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 70.161% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | -89.711% |
| Athira Pharma, Inc. | -125.46 Million USD | -9.532% |
| Vaccinex, Inc. | -22.88 Million USD | -500.503% |
| HCW Biologics Inc. | -25.71 Million USD | -434.371% |
| XOMA Corporation | -41.84 Million USD | -228.391% |
| Arvinas, Inc. | -401.5 Million USD | 65.772% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -1553948.782% |
| Merus N.V. | -156.54 Million USD | 12.215% |
| Omega Therapeutics, Inc. | -100.26 Million USD | -37.067% |
| Quince Therapeutics, Inc. | -34.62 Million USD | -296.953% |
| Rezolute, Inc. | -70.42 Million USD | -95.142% |
| Clene Inc. | -40.54 Million USD | -238.986% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | -739.059% |
| BeyondSpring Inc. | -23.11 Million USD | -494.553% |
| Synlogic, Inc. | -55.16 Million USD | -149.134% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | -666.496% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | -1169.632% |
| Peak Bio, Inc. | -1356.23 USD | -10132768.319% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | -239.296% |
| Krystal Biotech, Inc. | -109.72 Million USD | -25.243% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | -6.087% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 59.936% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | -2795.625% |
| MannKind Corporation | 8.67 Million USD | 1683.602% |
| Ikena Oncology, Inc. | -75.41 Million USD | -82.22% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | -1324.536% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | -104.41% |
| Gossamer Bio, Inc. | -183.75 Million USD | 25.215% |
| CohBar, Inc. | -12.38 Million USD | -1009.313% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | -170.927% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | -398.151% |
| Legend Biotech Corporation | -439.48 Million USD | 68.73% |
| Mural Oncology plc | -194.63 Million USD | 29.395% |
| Biora Therapeutics, Inc. | -67.14 Million USD | -104.675% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -751.178% |
| Disc Medicine, Inc. | -91.12 Million USD | -50.809% |
| Champions Oncology, Inc. | -7.35 Million USD | -1768.203% |
| REGENXBIO Inc. | -268.12 Million USD | 48.746% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -1182.166% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -146.476% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | -252.728% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | -20.172% |
| Vaxart, Inc. | -83.34 Million USD | -64.883% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | -1512.968% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | -221.131% |
| Cellectis S.A. | -106.62 Million USD | -28.885% |
| Longeveron Inc. | -21.02 Million USD | -553.502% |
| Repare Therapeutics Inc. | -116.22 Million USD | -18.241% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 48.688% |
| Inozyme Pharma, Inc. | -75.64 Million USD | -81.671% |
| Revolution Medicines, Inc. | -487.18 Million USD | 71.792% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | -1965.92% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | -212.656% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | -84.241% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | -97.35% |
| Anixa Biosciences, Inc. | -11.01 Million USD | -1148.07% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 103.19% |
| Denali Therapeutics Inc. | -196.69 Million USD | 30.134% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -1487.505% |
| Veru Inc. | -93.78 Million USD | -46.536% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | -489.074% |
| Cingulate Inc. | -22.75 Million USD | -503.822% |
| Passage Bio, Inc. | -108.38 Million USD | -26.789% |
| Context Therapeutics Inc. | -25.07 Million USD | -448.108% |
| Exicure, Inc. | -14.99 Million USD | -816.411% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 33.31% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | -238.502% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | -1314.283% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 25.457% |
| Nuvalent, Inc. | -149.49 Million USD | 8.072% |
| ABVC BioPharma, Inc. | -8.21 Million USD | -1572.547% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | -54.878% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | -561.524% |
| OmniAb, Inc. | -69.41 Million USD | -97.965% |
| Anew Medical, Inc. | -1.3 Million USD | -10464.328% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | -976.071% |
| Lipocine Inc. | -17.93 Million USD | -666.412% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | -100.582% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | -80.461% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | -260.929% |
| G1 Therapeutics, Inc. | -39.52 Million USD | -247.674% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | -513.943% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 76.3% |
| Ocugen, Inc. | -65.53 Million USD | -109.71% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | -46.406% |
| Q32 Bio Inc. | -92.1 Million USD | -49.21% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | -541.005% |
| Alumis Inc. Common Stock | -158.17 Million USD | 13.118% |
| Equillium, Inc. | -14.52 Million USD | -846.323% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | -120.211% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -1638.82% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -628.461% |
| Galera Therapeutics, Inc. | -46.95 Million USD | -192.699% |
| Evelo Biosciences, Inc. | -108.46 Million USD | -26.699% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -1048.077% |
| Dominari Holdings Inc. | -21.79 Million USD | -530.506% |
| Edesa Biotech, Inc. | -9.22 Million USD | -1390.064% |
| vTv Therapeutics Inc. | -25.5 Million USD | -438.879% |
| Bio-Techne Corporation | 206.68 Million USD | 166.49% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 64.897% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | 171.564% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | -3.892% |
| Candel Therapeutics, Inc. | -38.39 Million USD | -257.962% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 9.051% |
| Nkarta, Inc. | -131.65 Million USD | -4.387% |
| BioCardia, Inc. | -11.64 Million USD | -1080.222% |
| Iterum Therapeutics plc | -47.46 Million USD | -189.511% |